Intellia Therapeutics Presents Promising In Vivo CRISPR Results

Summary

• Intellia Therapeutics has released positive data from its Phase I/II study of NTLA-2002, a CRISPR-based gene editing therapy.
• The study shows promising results for in vivo gene editing, offering potential treatments for genetic diseases.
• Robust target engagement and efficacy data pave the way for future Phase II results from Intellia later this year.
• Intellia has the most advanced in vivo gene editing portfolio, which, while speculative, could represent a huge advance for the field in coming years.

CRISPR-Cas9 genome editing enzyme

Artur Plawgo

Intellia Therapeutics (NASDAQ:NTLA) recently reported strong data from the Phase I portion of an ongoing Phase I/II study for NTLA-2002, an in vivo CRISPR-based gene editing therapy for hereditary angioedema (HAE). I have previously written about

Analyst’s Disclosure:I/we have a beneficial long position in the shares of NTLA either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Disclaimer: All investment opportunities carry inherent risk, including potential loss of principle. Carefully consider your investment objectives, level of experience and risk appetite before making any investment. The above discussion is a framework for investors (both long and short), to understand the factors that will move the underlying security’s price. It is not a prediction and should not be considered investment advice. The author also has a beneficial long position in shares of CRSP.